AI Article Synopsis
- Thyroid cancer stem cells (TCSCs) are important in understanding thyroid cancer's progression and treatment, highlighting their potential as biomarkers and therapeutic targets.
- A systematic review analyzed five articles and identified six TCSC markers (CD133, CD44, CD24, CD15, and ALDH1) linked to thyroid cancer prognosis.
- More research is needed to confirm the clinical effectiveness of these markers for predicting patient outcomes in thyroid cancer.
Article Abstract
Introduction: Thyroid cancer stem cells (TCSCs) play a crucial role in the pathogenesis, metastasis, and therapeutic response of thyroid cancer, making them promising biomarkers and potential targets for clinical intervention. This systematic review aims to qualitatively assess the impact of commonly used TCSC markers on the prognosis of thyroid cancer using qualitative methods.
Methods: In total, the analysis encompassed five articles.
Results: Six TCSC markers were involved, among which CD133, CD44, CD24, CD15 and ALDH1 were associated with the prognosis of thyroid cancer.
Conclusions: However, the utility of these TCSC markers in clinical practice for predicting the prognosis of thyroid cancer requires further research to provide additional evidence supporting their effectiveness.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11094817 | PMC |
| http://dx.doi.org/10.5114/aoms/185169 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!